Can we count your visit with Google Analytics? No ads, no profiles. Details
MRK
USHealth Care · Pharmaceuticals
Each weekday: the watchlist of pullbacks inside uptrends, every new ticker teardown, and the bubble shifts that move names like this one. Free. Education, not advice.
Free when you join: the $HOOD Teardown Dossier (Robinhood Markets), the full desk file we sell in the shop. One per new reader.
No spam. One email per day max, unsubscribe in one click. Pro ($49/mo) includes every dossier and report in the shop.
Structural read: $MRK is a single-asset story trading on Keytruda concentration risk vs. pipeline-replacement credibility into the 2028 LOE. Keytruda is ~45-50% of pharma revenue at a >$25B/yr run-rate, and the subcutaneous reformulation (Keytruda Qlex) is the primary lifecycle-extension lever - early uptake and payer coverage are the gating variables for how much revenue carries past the IV biosimilar cliff.
Animal Health and Vaccines (Gardasil, Pneumovax) provide a $15B+ non-oncology base. The bull/bear gap is wide because the post-2028 pipeline (Winrevair PAH, oral PCSK9, ADC platform via Daiichi Sankyo collab, cardiometabolic) has to compound through M&A and clinical readouts to fill the hole.
It reads our $MRK data (thesis, key levels, peers, a year of prices) and any chart screenshot you paste, then explains the setup in plain English. Free with an email login, 5 questions a day. Education only: it never tells you to buy or sell, and it can be wrong, so check the numbers.
High-signal only
Auto-computed retracement of the trailing 52w low-high leg. Recomputed on each refresh; not a curated level.